Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of NGM282 in primary sclerosing cholangitis
2015-003392-30Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing NGM282 with Placebo (2 arms). Primary endpoint: Change in alkaline phosphatase at Week 12. Started Dec 2015; status: completed.
02
Drugs
aldafermin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2015-003392-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003392-30.